Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

ITM Receives Complete Response Letter for ¹⁷⁷Lu-edotreotide (ITM-11)

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at markets.businessinsider.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

ITM received a Complete Response Letter from the FDA for its ITM-11 drug application, citing Chemistry, Manufacturing, and Controls (CMC) and third-party facility inspection issues, with no safety or efficacy concerns.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

FDA’s manufacturing-related hold on ITM-11 means your therapy must meet stricter production and inspection standards before market entry. Addressing these could open early access in US oncology despite clinical data clearance.

◆ Coverage

1 source · 10 Aug 2026

◆ Related on Wire

◆ Topics

Biotechfda-crldrug-approval-delayclinical-trialradiopharma